Analyst Expectations For Haemonetics's Future
Portfolio Pulse from Benzinga Insights
Haemonetics (NYSE:HAE) has received mixed analyst ratings over the past three months, with a current average price target of $107.5. Analysts have adjusted their ratings and price targets in response to market conditions, with some maintaining or raising their outlook. Haemonetics has shown solid financial performance, with notable revenue growth and strong profitability metrics.

August 22, 2024 | 4:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Haemonetics has received mixed analyst ratings, with a current average price target of $107.5. Analysts have adjusted their ratings and price targets, reflecting varied expectations. The company's strong financial performance, including revenue growth and profitability, supports a positive outlook.
The mixed analyst ratings, with a majority being somewhat bullish or neutral, suggest a stable to positive short-term outlook for Haemonetics. The company's strong financial performance, including revenue growth and profitability, further supports this positive sentiment. The adjustments in price targets by analysts indicate a response to recent market conditions and company performance, which could lead to a slight upward movement in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100